(MYGN) Myriad Genetics Expects Fiscal Year 2025 Revenue Range $840M - $860M
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.93 USD | +4.19% |
|
+3.11% | -5.69% |
Feb. 05 | Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay | MT |
Feb. 05 | Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration